3 Must-Own Healthcare Stocks For Your Portfolio

For its fiscal second quarter, ended June 30, 2021, LH’s revenues were  $3.84 billion, representing a 38.7% increase from the prior-year period. The company’s gross profit increased 66.3% year-over-year to $1.26 billion. Its adjusted operating income has been reported at $839.90 million for the quarter, up 120.6% from the prior-year period.

While its adjusted net income increased 140% year-over-year to $602.40, its adjusted EPS increased 138.5% year-over-year to $6.13. The company had $1.96 billion in cash and cash equivalents as of June 30, 2021.

For the current year, analysts expect LH’s revenue to be $14.73 billion, representing a 5.4% rise from the prior-year period. The stock has surpassed consensus EPS estimates in each of the trailing four quarters. LH has rallied 47.7% over the past nine months and 6.8% over the past month. It has been recently trading at around $296.15.

LH’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which equates to Buy in our proprietary rating system. The stock has a B grade for Growth, Quality, and Value. We also have graded LH for Stability, Sentiment, and Momentum. Click here to access all LH ratings. LH is ranked #4 of 55 stocks in the Medical – Diagnostics/Research industry. 

Bruker Corporation (BRKR)

BRKR manufactures and distributes proprietary life science systems and advanced materials research tools based on X-ray technology platforms. The company also sells a range of field analytical systems for substance detection and pathogen identification. BRKR is based in Billerica, Mass.

On June 21, BRKR launched a new VIP-HESI ion source and new integrated software tools to increase confidence in 4D-Metabolomics and 4D-Lipidomics workflows. BRKR’s collaborators are making major progress in 4D-Metabolomics by leveraging measured collision cross sections (CCS). These CCS values will be useful in the annotation of unknown compounds and bring a step-change for untargeted metabolomics and lipidomics research.

On June 7, BRKR announced the launch of the FluoroTypeSARS-CoV-2 varID Q assay, which detects SARS-CoV-2 mutations enabling laboratories to differentiate many major viral variants routinely on all positive samples. Providing improved statistics for epidemiology, with shorter (overnight) time-to-result (TTR), and lower costs than NGS, this assay is likely to witness widespread recognition in the industry in the near-term.

View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.